Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.
|
|
- Felicity Boone
- 5 years ago
- Views:
Transcription
1 Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A.
2 CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure Faculty: G Michael Allan (Mike) Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria: None Consulting Fees: None Other: None
3 CFPC CoI Templates: Slide 2 Disclosure of Commercial Support This program has received financial support from Ontario College of Family Physicians in the form of honorarium and flight. This program has received in-kind support from Alberta College of Family Physicians and the U of A in the form of My team grant and my salary, respectively. Potential for conflict(s) of interest: Mike has received nothing from anyone with a commercial interest. a product that will be discussed in this program: Not relevant.
4 CFPC CoI Templates: Slide 3 Mitigating Potential Bias I will try not to talk (too much) about the merits of primary care.
5 Case: Mr Chole needs some help Mr Chole is 50 years old. He is thick around the middle, has elevated sugar (but not Diabetes), is on 2 drugs for hypertension, and thinks beer is staving off heart disease. Non-smoker & no family history. Total cholesterol: 6.2 mmol/l HDL: 0.75mmol/L LDL: 4.5 mmol/l Triglycerides: 5 mmol/l What is his 10-year risk of any CVD It is about a 22% 10-year risk of CVD What drug would you consider & what are the benefits of treatment?
6 Statins: Primary Prevention Hard to get Clean data, lots of heterogeneity, Meta-analysis of DM 1 : 37% of Diabetics, History of CVD Meta-analysis of Primary Prevention 2 : Includes diabetics Meta-analysis of all 3 Complete mix of patients Done per mmol/l reduction 1. Lancet 2008; 371: BMJ 2009;338:b2376. doi: /bmj.b Lancet 2005; 366:
7 Statin: Primary Prevention 10 RCT (70 K pts) 1 ; mean 4.1 yrs, low-mid dose, CVD 5.3% vs 3.8%, NNT 66 Others find (for 5 yrs) CVD NNT = 40 primary prevention But NNT will change based on base-line risk Relative risk reduction is stable: 25% 1. BMJ 2009;338:b2376. ACP J Club 2009; 151(4): Lancet 2005; 366: ) Cochrane Database Syst Rev Jan 31;1:CD
8 1. Am J Med. 2008;121: ACP J Club 2008; 149(1): 7. Lancet Neurol 2009; 8: Cochrane Database Syst Rev Jan 31;1:CD CMAJ Nov 8;183(16):E1189- Stroke (& MI) Individually Stroke: Mixed population (Primary & Secondary) Meta-analysis (121 K pts) 1 : 3.0% vs 3.6%, NNT 174 Relative reductions of stroke and MI are 2 27% - 36% for MI 19% - 22% for stroke.
9 A closer look at the statins don t reduce mortality (in primary prevention)?
10 Primary Prevention & Statin Bottom-line: In primary prevention, statins reduce Mortality about 0.5% over 5 years (or about 10% relative). They reduce CVD by 25%. In our case, Mr Chole would have his risk go from 22% to 16.5%, A reduction of 5.5% or NNT of 19 over 10 years.
11 1. N Engl J Med 2008;358: N Engl J Med 2009;361: N Engl J Med 2008;359: Lancet. 2011;377(9784): N Engl J Med 2008;359: Ezetimibe Statin + Ezetimibe vs Statin + placebo RCT 1, 720 pts, fam. hyperchol, 46y.o, 50% : Nothing RCT 2, 363 pts (208 analyzed for part), CAD (77%) or equiv. CVD events: 5% Ezetimibe vs 1% Niacin. NNT 24 Statin +Ezetimibe vs placebo SEAS trial 3 : 1873pts, asymptomatic aortic stenosis x4.5 yrs, Nothing SHARP 4 : 9438 renal impaired pts, 5 years, 11.3% vs 13.4% combined CVD events. (no diff in mortality) Cancer: 3 largest studies combined, Concern of more cancer deaths (0.2%/year extra) 5
12 Ezetimibe Bottom-line: It should not be used until we have some better data to support it Most Important: IMPROVE-IT (Primary trial ) Does ezetimibe add anything to CAD patients on statin? 2011: No benefit, Extend 1 year 2012: No benefit, Extend 2 years.
13 Fibrates 8 systematic reviews evaluate fibrates. 1-8 Heterogeneity common but trial results similar Meta-analysis 1 of 18 trials (45,058 pts) x1-6 years RRR 10% (0-18%) in CVD Primarily due to a 20% RRR in non-fatal coronary events No effect on all-cause or vascular mortality, or stroke When added to a statin (5518 diabetics x 4.7 yrs) No difference in any outcome 1) Lancet. 2010;375: ) Am J Med. 2009;122:962.e1-962.e8. 3) Am Heart J. 2007;154: ) Curr Opin Lipidol. 2006;17(4): ) Am J Ther. 2010;17(6):e ) Int J Cardiol. 2010;141(2): ) J Am Coll Cardiol 2005;45: ) Arch Intern Med. 2005;165: ) N Engl J Med Apr 29;362(17):
14 Fibrates Reduce pancreatitis (by reducing triglycerides). The best evidence 13 suggests the opposite: Statins reduce pancreatitis (NNT 1200 at 5 years) Fibrates increase pancreatitis (NNH 935 at 5 years) Bottom-line: Seems to improve non-fatal MI in mixed group with higher risk, no help with mortality and some concerns linger. JAMA. 2012;308:
15 Niacin: Vitamins, Always healthy RCT 3414 pts CVD hx, x3 yr, Niacin added statin Outcomes: Stopped early as no benefit Strokes approaching borderline stat sign worse Flushing 3.3% vs 1.4% Otherwise, research is old (late 1960 s): Coronary Drug Project (15 years), 3908 x 4 arms 27% relative reduction CVD outcomes 2 (esp non-fatal MI) Bottom-Line: Probably no place at this time. Boden WE et al. N Engl J Med. doi: /nejmoa EurJ Clin Pharmacol (1991) 40 [Suppl 1]: S49-S J Am Coll Cardiol 2005;45: N Engl J Med 2009;361:
16 Omega 3 or n-3 Fatty Acids Meta-analysis 1 : 14 RCTs, pts, No benefit on overall CV events RR 0.99 (CI ) No benefit all cause mortality, MI, stroke, etc RCT 12,536 diabetics (60% with CVD): no effect RCT 12,513 CVD (non-mi): No effect Only cohort data & weakest RCTs support benefit 3 Bottom-Line: No effect. 1) Arch Intern Med Apr 9. 2) Lancet 1971;1(7710): ) BMJ 2006; 332:
17 Diet No data for any but the Mediterranean Diet. Primary Prevention Med Diet (PREDIMED) 7447 pts, 57% women, age yrs, 4.8 yrs. Fresh fruit 3 + /d, vegies 2 + /d, legumes 3 + /wk, fish-seafood 3 + /wk, white meat vs red (red & processed <1/d) All CV events: 29% relative reduction, 4% vs 5.6%, NNT 77 Countries Risk CVD Mortality Lancet 1994 France Secondary (MI within 6 months) 0.27 ( ) 0.30 ( ) Lancet 2002 Northern India Mixed ( 1 risks (BP, Chol, DM), or angina or MI)* 0.50 ( ) 0.63 (not sign, p=0.064) BMJ 2008;337:a1344 Lancet 1994; 343: Lancet 2002; 360: Estruch NEJM 2013
18 Torcetrapib: The Lipid King Cholesteryl ester transfer protein (CETP) Inhibitor HDL up 72% (34 mg/dl), LDL down 25% (22mg/dL) Unfortunately 1 : CVD events sign 25%, AR = 1.2%, NNH 84 Mortality sign 58%, AR = 0.45%, NNH 222 Withdrawn Dalcetrabip also developed stopped Anacetrapib still in development 2 Good Lesson about Surrogates and Targets 1. N Engl J Med 2007;357: Canon CP et al, N Engl J Med 2010.
19 Secondary Prevention
20 Is bigger better: High Dose Statin At least 6 meta-analyses 1-6 Most recent: 10 trials, 41,778 patients with cardiovascular disease (CVD). Mean trial duration 2.5 years. High dose usually Atorvastatin 80mg. Low-moderate dose varies: pravastatin 40 mg to lovastatin 5mg. Outcomes No difference Death, CVD death, or fatal MI. High dose Heart disease: 9.4% vs 10.5%, NNT 91 over 2.5 yrs Others add some clarity but little difference. High dose, Reduced mortality: NNT 91 over 2 years in ACS patients 1,3 Increased adverse events leading to stopping therapy: NNH 47
21 Is Bigger Better? Statin (low-moderate: 40mg Pravastatin or 20-40mg Simvastatin) vs placebo CHD: 7 Reduced CHD: NNT 27 Reduced Mortality: NNT 56 Benefits of low-moderate dose vs placebo are much more than high dose vs low-moderate dose (relative benefits 25% 7 vs 10% 1 ). Adherence to statin therapy in the community is poor: Up to 50% stop taking statins by 3 years adverse events play a role in these discontinuations Muscle-related side effects and transaminase abnormalities increase 4-5 fold going from atorvastatin 40 mg to 80 mg. 11,12 1) European Heart Journal (2011) 32, ) Lancet 2010;376: ) CMAJ
22 Is Bigger Better? Bottom-line: In patients with coronary artery disease, using high dose statins (compared to low-moderate dose) prevents one CHD event for every 91 patients, but results in one in 47 patients discontinuing therapy due to adverse events. However, low-moderate dose statin (compared to placebo) provides 2-3 times greater benefit that increasing to high dose. Therefore, getting and keeping patients on any statin is key, with dose adjusted up to tolerable levels. 1) European Heart Journal (2011) 32, ) Lancet 2010;376: ) CMAJ 2008;178: ) Clin Ther 2007;29: ) Heart 2007;93: ) J Am Coll Cardiol 2006;48: ) Arch Intern Med ;164(13): ) Expert Opin. Pharmacother. 2009;10(18): ) J Epidemiol Community Health 2010;64:109e ) Stroke. 2007;38: ) Expert Opin Drug Saf 2010; 9(4): ) Am J Cardiol 2002; 90 Suppl:50K-60K
23 What Experts Say Low Risk: Recommend pharmacotherapy for LDL 5.0 mmol/l, or if genetic dyslipidemia (Strong Rec, Moderate- Evidence). Target 50% reduction of LDL (Strong Rec, Mod- Evid). Intermediate Risk (Framingham risk score 10-20%): Treat for LDL 3.5 mmol/l (Strong Rec, Mod- Evid). Target LDL 2.0 mmol/l or 50% reduction of LDL-C (Strong Rec, Mod Evid). High Risk (Framingham 20%) Target LDL 2.0 mmol/l or 50% reduction of LDL-C (Strong Recommendation, High- Evid). Plus Other testing optional (apo, etc) Canadian Journal of Cardiology 29 (2013)
24 Reviewing the Target trials Trials that target lipid levels (please fill in when we get a single study) Trials that triage & treat based on other markers (please fill in when we get a single study) Jupiter enrolled moderate risk pts with higher CRP but did not treat or randomize by this selection The Actual evidence is low quality
25 Struggling for Clarity
Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationManaging Back Pain. Faculty/Presenter Disclosure
Managing Back Pain G. Michael Allan Evidence & CPD Program, Alberta College of Family Physicians Professor, Dept Family Med, U of A. Faculty/Presenter Disclosure Faculty/Presenter: G. Michael Allan Relationships
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationControversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationRobyn Cruz, PharmD, BCPS, BCPP 1
Robyn Cruz, PharmD, BCPS, BCPP ISHP Spring Meeting April 2014 Identify major changes in treating hyperlipidemia according to the 2013 ACC/AHA Blood Cholesterol Guidelines Discuss clinical trial data that
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationTop 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008
Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationNew, True & Poo. Faculty/Presenter Disclosure
New, True & Poo Unpleasant Truths Comforting Lies Tina, Mike K, Adrienne, Mike A, Evidence & CPD Program, Alberta College of Family Physicians Department of Family Medicine, University of Alberta Faculty/Presenter
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationESC, ACC/AHA and Malaysian CPG Guidelines on lipids Statins Introduction to non-statins Guideline recommendations for non-statins Clinical trials of
ESC, ACC/AHA and Malaysian CPG Guidelines on lipids Statins Introduction to non-statins Guideline recommendations for non-statins Clinical trials of non-statin drugs Non-statin vs placebo Non-statin vs
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More information9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure
2013 AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis Robert Gleeson MD Preven5ve Cardiology and Lipid Management Froedtert and The Medical College of Wisconsin Disclosure
More informationHyperlipidemia in an Otherwise Healthy 80 Year-Old Patient. Theodore D Fraker, Jr, MD Professor of Medicine
Hyperlipidemia in an Otherwise Healthy Theodore D Fraker, Jr, MD Professor of Medicine Orlando, Florida October 7-9, 2011 80-Year-Old Patient Primary Prevention Issues in the Elderly: Coronary artery disease
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationCCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018
CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update November 17 th, 2018 Faculty/Presenter Disclosure Faculty: Rick Ward Relationships with commercial interests: Grants/Research Support:
More informationDYSLIPIDEMIA. Michael Brändle, Stefan Bilz
DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention
More informationLow HDL-levels: leave it or treat it?
Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationWelcome to the 19th Annual wow, almost 20 years Drug Therapy Decision Making Course
Welcome to the 19th Annual wow, almost 20 years Drug Therapy Decision Making Course An interactive course on common and new drug therapy issues from an evidence based perspective Education should not be
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationThe Mediterranean Diet: The Optimal Diet for Cardiovascular Health
The Mediterranean Diet: The Optimal Diet for Cardiovascular Health Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health Cardiovascular Disease Prevention International
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More information